Рубрика
Blog
-
2023
-
FDA rejects Eli Lilly’s mirikizumab for ulcerative colitis, citing manufacturing concerns
-
Regenxbio Gene Therapy Candidate Gets Fast Track Status for Duchenne Muscular Dystrophy
-
FDA Accepts sBLA for Pembrolizumab Plus Chemotherapy in Advanced Gastric/GEJ Adenocarcinoma
-
The FDA Commissioner Who Approved the Abortion Pill Is Still Fighting for It
-
Biogen to develop amyloid beta-targeting antibody platform
-
Sumitomo Pharma’s Ewing Sarcoma Candidate Gains Orphan Drug Status
-
Potential Nitrosamine Contamination Results in Another Voluntary Pharmaceutical Recall
-
Idorsia Urges DEA to Deschedule Chronic Insomnia Drug Class
-
US FDA advisers to weigh full approval for Eisai-Biogen’s Alzheimer’s drug
-
Merck, Eisai decide to discontinue advanced melanoma therapy trial